生物活性：Fumonisin B1-13C34 is the 13C labeled Fumonisin B1 (HY-N6719)[1]. Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin[2][3].
IC50 & Target：Sphingosine N-acyltransferase[2]
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。Fumonisin B1 改变猴肾细胞基因表达和信号转导通路[2]。
Fumonisin B1 增加鞘脂代谢的初始破坏和鞘氨醇在 LLC-PK1 肾细胞中的积累，导致大鼠星形胶质细胞凋亡型 DNA 损伤[2]。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量：755.58
Formula：13C34H59NO15
CAS 号：1217458-62-2
非标记 CAS：116355-83-0
中文名称：伏马菌素B1-13C34
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220.
 [Content Brief]
[2]. Henry MH, et al. The toxicity of fumonisin B1, B2, and B3, individually and in combination, in chicken embryos. Poult Sci. 2001 Apr;80(4):401-7.
 [Content Brief]
[3]. Wang SK, et al. Effect of fumonisin B₁ on the cell cycle of normal human liver cells. Mol Med Rep. 2013 Jun;7(6):1970-6.
 [Content Brief]